Ormeloxifene (Centchroman) Cancer Research Results

ORM, Ormeloxifene (Centchroman): Click to Expand ⟱
Features:

Ormeloxifene (Centchroman) — Nonsteroidal selective estrogen receptor modulator (SERM) originally developed as a once-weekly oral contraceptive. Ormeloxifene exhibits tissue-selective estrogenic and anti-estrogenic effects, including strong anti-estrogenic activity in breast tissue and modulation of estrogen signaling in the endometrium.

Drug class: Selective Estrogen Receptor Modulator (SERM) / nonsteroidal anti-estrogen / repurposed anticancer drug.

Primary clinical uses: Oral contraception, mastalgia, fibroadenoma, and selected gynecologic disorders. Ormeloxifene has been used clinically in India for decades.

Cancer relevance: Moderate to strong preclinical evidence with limited clinical evidence. Ormeloxifene has demonstrated antiproliferative, pro-apoptotic, anti-invasive, and antimetastatic effects in breast, ovarian, head-and-neck, pancreatic, prostate, and hematologic cancer models. Early clinical studies in advanced breast cancer also reported objective responses in a subset of patients.

Typical mechanisms: Estrogen receptor signaling modulation; proliferation ↓; cell-cycle progression ↓; apoptosis ↑; BAX ↑; BCL2 ↓; caspase activation ↑; PI3K/AKT signaling ↓; MAPK/ERK signaling ↓; NF-kB signaling ↓; migration ↓; invasion ↓; EMT ↓. Mechanisms vary by tumor type and may include estrogen-receptor-independent effects.

Estrogen receptor relevance: Ormeloxifene is a SERM rather than a pure estrogen receptor antagonist. Its effects are tissue-selective and should not be interpreted as universal ESR1/ESR2 inhibition.

Pharmacokinetics: Ormeloxifene has a long elimination half-life, approximately 168 hours, supporting once-weekly contraceptive dosing.

Recommended product classification: Drug — SERM / Repurposed Anticancer Drug.



Scientific Papers found: Click to Expand⟱
8846- DIM,  ORM,    Diindolylmethane Promotes Metabolic Crisis and Enhances the Efficacy of Centchroman in Breast Cancer: A 1H NMR-Based Approach
- vitro+vivo, BC, NA
AntiCan↑, EPR↑, Synergy↑, TumCG↓, Glycolysis↓, PKM2↓, GLUT1↓, Hif1a↓, eff↑, Glycine↓, Alanine↓, toxicity↓, Dose↝, TumW↓, Ki-67↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

Alanine↓, 1,   Glycine↓, 1,   Glycolysis↓, 1,   PKM2↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

Ki-67↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCG↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 1,   GLUT1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 1,   Synergy↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↓, 1,   TumW↓, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:497  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page